Posts tagged “Alternative Treatments”

2026 real-world study: 84.4% of cancer patients taking ivermectin and mebendazole reported clinical benefit at 6 months, with nearly half seeing tumor reduction.

Preprint report on 197 cancer patients prescribed compounded ivermectin and mebendazole shows 84.4% clinical benefit ratio at 6 months, with key limitations noted.

Methylene blue, an FDA-approved drug for methemoglobinemia, is being studied in preclinical cancer research for its redox-cycling, ROS, and PDT mechanisms.